Clinical Research Directory
Browse clinical research sites, groups, and studies.
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences
Summary
The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- DB8 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- DB8. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- DB8 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.
Official title: SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 ([99mTc]Tc- DB8) in Prostate Cancer and Breast Cancer Patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-07-03
Completion Date
2024-12-31
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
Intravenous injection of [99mTc]Tc-DB8
One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Locations (1)
TomskNRMC
Tomsk, Russia